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Abstract
Background: Stroke incidence increases with age. Atrial fibrillation (AF) is an important risk factor for ischemic stroke 
and its incidence also increases with age. However oral anticoagulant therapy (OAT) tends to be underused in the 
elderly population.
Methods: Elderly patients (> = 80 years) with an ischemic stroke admitted in our department between 1/7/2003 and 
31/6/2005 were prospectively evaluated. Baseline characteristics, risk factors, treatment and etiology according to 
TOAST criteria were recorded. Patients treated with OAT were followed up in order to assess any side effect and stroke 
recurrence. Mean follow-up was of 19.5 months (7-45) from discharge.
Results: Sixty four out of a hundred and fifty nine elderly patients (40.25%) were classified as cardioembolic; mean age 
was 84.5 years (80-97) and 64.6% were women. AF had been previously identified in 60% of them (16.9% were on OAT 
and 40.6% on antiplatelet therapy). At discharge, 32 patients (49.2%) were on OAT. In the follow-up 4 patients (12.5%) 
suffered systemic haemorrhages (3 urinary, 1 gastrointestinal bleeding), with no change in their functional status. Mean 
INR in this group was 5.9 [3-11] and, in 3 of them, OAT was cancelled. No brain haemorrhages were recorded. Ischemic 
stroke recurred in 4 patients (INR < 1.8 in 3 of them; the other, INR 2.35). Three patients had died at the end of the 
follow-up, one of them as a consequence of ischemic stroke recurrence.
Discussion: Twenty eight point eight of stroke patients admitted in the period of study were >80 years. The high 
proportion of cardioembolic strokes in this age segment contrasts with the general underuse of OAT as antithrombotic 
prophylaxis. Our study suggests that OAT is a safe strategy when carefully prescribed, even for elderly patients.
Introduction
Atrial fibrillation (AF) is present in more than 5% of >65
year-old population, increasing with age, as it is present
in 10% of people ≥ 75 years [1]. Cardioembolism is the
etiology in approximately 25% of strokes in patients age ≥
80 years [2]. It is also known that paroxistic AF, very com-
mon in elderly people, raises the same risk of stroke as
chronic AF [3]. Non-valvular atrial fibrillation (NVAF) is
the most common cause of arrythmia, as the frequency of
reumathic valvulopathy falls [1]. AF predisposes to left
atrial thrombus formation and carries a sixfold increased
anual risk for stroke, rising from 1.5% for those aged 50-
59 years to 23.5% for those aged 80-89 years [1], [3]. Such
cardioembolic strokes are very often more severe than
other ischemic strokes, and are associated to a higher
mortality [4], [5], [6]. The annual embolic rate attributed
to AF is approximately 12% for patients >65 years-old [7],
[8], [9]. It has been shown that the NIHSS and modified-
Rankin scales, patients on oral anticoagulation therapy
show less serious strokes and present a better functional
situation at discharge than those who were not on that
treatment [10]. This seems to endure as a controversial
subject that leads physicians to a difficult decision when
they prescribe these patients antithrombotic profilaxis.
The main objective or our study was to prospectively
assess the efficacy and safety or oral anticoagulants (OA)
in ≥ 80 year-old population as secondary prophylaxis of
cardiembolic strokes.
Subjects and Methods
This is an observational prospective study conducted in
tertiary hospital that covers an area of 400,000 habitants
and it is the reference hospital of a department of one
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million habitants. To be eligible, patients had to be ≥ 80
years of age and a diagnosis of ischemic stroke or tran-
sient ischemic attack (TIA) had to be present. According
to these inclusion criteria 159 patients were consecutively
selected among all the stroke patients admitted in our
Neurology Department starting July 1 st 2003 until June
31st 2005. We analysed clinical characteristics, cardiovas-
cular risk factors, previous treatment and at discharge
treatment and follow-up, but also classified the stroke eti-
ology according to TOAST criteria [11]. Patients treated
with oral anticoagulants were followed up through peri-
odical reviews, the first one at our Outpatient Clinic, 3
months from discharge; after that we have been in con-
tact with the patients by phone every 6 months.
At admission in the Emergency Department, a brain
computerized tomography (CT), blood ancillary tests
including hemogram, glucose, electrolytes, vitamins,
renal, liver and thyroid function, lipids, coagulation and
INR (International Normalized Ratio) if having oral anti-
coagulants; electrocardiogram and thoracic radiography
were performed in all patients.
Demographic data were recorded for all 159 patients,
including age and sex, social status, previous treatment
and treatment at discharge, previous stroke incidence
(TIA, brain infarction or haemorrhagic brain infarction)
or other neurological diseases. Other cardiovascular risk
factors were also studied, including previous diagnoses of
hypertension (BP ≥ 140/90), diabetes (basal glycaemia ≥
110 mg/dl), dyslipemia (total cholesterol ≥ 220 mg/dl or
LDL-cholesterol ≥ 160 mg/dl), ischemic cardiopathy,
myocardiopathy, peripheral artery disease, smoking (one
of more cigarettes per day) or alcohol intake (≥40 g/day).
The severity of stroke and functional outcome were
reflected by NIHSS, Barthel and Modified-Rankin scales.
The etiological classification has been led according to
TOAST criteria [11] after practising ancillary studies,
such as carotid ultrasonographic study, transcranial Dop-
pler, Holter monitoring, echocardiogram and other spe-
cific blood analyses on an individual basis. Therefore, the
strokes were classified as "cardioembolic strokes", "large-
artery atherosclerosis", "small-artery occlusion", "stroke
of other determined etiology" and "stroke of undeter-
mined etiology".
We selected those patients diagnosed with cardioem-
bolic stroke according to TOAST classification, summa-
rizing 64 patients (42.1%) out of the total of the sample.
According to the social status, risk of falls and mainly
neurological and functional scales, we treated 32 of them
(40.9%) with oral anticoagulants, avoiding this treatment
in case of patients without social support, high risk of
falls or m-Rankin score over 3. We have followed them
up, analysing the adverse events related to these drugs
and the clinical outcome.
Results
F ive hundred and thirty patients were admitted in our
Department with a diagnosis of ischemic stroke. One
hundred and fifty nine of them (30%) were more than 80
years old and were selected for our study. Sixty five per
cent were females, thirty five per cent were males, and
mean age was 84.5 years. According to TOAST criteria,
cardioembolic strokes represented 40.25% (64) of our
patients, followed by large-artery atherosclerosis and
small-artery occlusion representing 4.1% of our patients
each. Fifty one point fifty five per cent were undeter-
mined, twenty per cent of them for coexisting different
etiologies. All the patients underwent electrocardiogram
and carotid ultrasonography; holter monitoring was
practised in 23% of patients and Echocardiography in
11.6% of patients.
Cardioembolic stroke population
Looking at the cardioembolic subgroup, the clinical diag-
nosis was transient ischemic attack (TIA) in 7.8%, brain
infarction in 90.6%, and haemorrhagic infarction in 1.6%.
Cardiovascular risk factors (CVRF), previous treatments
and neurological status at discharge are shown in Table 1,
and clinical and dependency scales at discharge are also
represented in Figure 1. Only 27% of patients with previ-
ously known AF were on anticoagulant therapy.
Cardioembolic stroke patients treated with oral 
anticoagulant
Out of all cardioembolic stroke patients, we treated with
OA 40.9% of them (n = 32). Gender, age, CVRF, social
Table 1: Clinical characteristics of cardioembolic stroke 
patients.
CARDIOVASCULAR RISK FACTORS
HT 107 (67.2%)
AF 92 (57.8%)
PREVIOUS STROKE 56 (35.1)
DIABETES 35 (21.9%)
ISCHEMIC CARDIOPATHY 30 (18.8%)
DYSLIPEMIA 21 (13.2%)
MYOCARDIOPATHY 15 (9.5%)
PERIPHERAL ARTERY DISEASE 5 (3.1%)
PREVIOUS TREATMENTS
ANTIHYPERTENSIVES 94 (59.4%)
STATINS 23 (14.3%)
ANTIPLATELETS 66 (41.3% )
ANTICOAGULANTS 25 (15.6%) (27% OF KNOWN 
AF)
Cardiovascular risk factors, previous treatments, dependency 
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support and clinical and dependency situation at dis-
charge are showed in Table 2, and clinical and depen-
dency scales at discharge are also represented in Figure 2.
Patients on OA therapy were followed for a mean of 19.5
months (7-45) and the adverse events related to oral anti-
coagulation were as follow: Four patients (12.5%) suffered
from a systemic haemorrhage: 3 had urinary bleeding and
1 had a gastrointestinal haemorrhage, although the M-
Rankin scale score was not modified in any case. The
mean INR in these patients was 5.95 [3-11]. On the other
hand ischemic recurrence affected another 12.5% (4
patients) whose INR was less than 1.8 in three of them
and an optimized level (INR = 2.35) in the other one.
Three patients died during the follow-up because of myo-
cardial infarction, pneumonia and recurrent ischemic
stroke respectively. Withdrawal of treatment occurred in
three cases, one because of a gastrointestinal haemor-
rhage, and the other two following the recommendations
of primary healthcare physicians. There was not any
intracranial haemorrhage.
Discussion
It has been previously demonstrated that AF is a powerful
risk factor for stroke. Our results show that AF is very fre-
quent among elderly stroke patients, rising cardioembolic
stroke etiology to 40.25%. Oral anticoagulants have been
proven to reduce the risk of stroke in AF by 68% com-
pared with placebo, which is superior to the relative risk
reduction of 21% associated with full-dose aspirin [12],
[13], [14], [10], [15], [16]. Even more, a recently published
study has suggested that aspirin at 150-200 mg per day is
neither effective nor safe [17]. Despite the modest or even
dubious effect associated to aspirin, this drug is widely
used in antithrombotic atrial fibrillation prophylaxis as in
spite of its proven benefits, numerous studies have docu-
mented an underuse of warfarin, particularly among
elderly patients who would seem to benefit the most from
anticoagulant therapy [18], [19]. However, OA as prophy-
lactic treatment are fourfold increased in people younger
than 80 years [17]. Haemorrhages, falls, and patient
refusal or a history of nonadherence to therapy consti-
tuted nearly 80% of the physician-cited reasons for not
prescribing warfarin to elderly patients [20], [21]. Other
studies conclude that patients at high risk for falls with
a t r i a l  f i b r i l l a t i o n  a r e  a t  s u b s t a n t i a l l y  i n c r e a s e d  r i s k  o f
intracranial haemorrhage, especially traumatic haemor-
rhage; nevertheless, because of their high stroke rate, they
appear to benefit from anticoagulant therapy if they have
multiple stroke risk factors [22], [23], [24], [25]. Moreover
it has been suggested that oral anticoagulation treatment
not only prevents stroke but may also contribute to the
Figure 2 Clinical and dependency scales at discharge.
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Figure 1 Clinical and dependency scales at discharge.
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Table 2: Clinical characteristics of cardioembolic stroke 
patients treated with oral anticoagulant.
GENDER AND AGE
SEX 40.6% male
AGE 83.2 (80-89)
CARDIOVASCULAR RISK FACTORS
HT 21 (65.6%)
AF 21 (65.6%)
DIABETES 7 (21.9%)
DYSLIPEMIA 6 (19.4%)
ISCHEMIC CARDIOPATHY 5 (15.7%)
MIOCARDIOPATHY 4 (12.9%)
CONGESTIVE CARDIOPATHY 
FAILURE
4 (12.9%)
SYSTEMIC EMBOLISM 
EVENTS
2 (6.3%)
PERIPHERAL ARTERY DISEASE 1 (3.1%)
SOCIAL SUPPORT
LIVING WITH FAMILY 27 (84.4%)
LIVING ALONE 4 (12.5%)
INSTITUTIONALIZED 1 (3.1%)Benavente et al. International Archives of Medicine 2010, 3:8
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development of less serious strokes with a better func-
tional prognosis [16], [26], [25].
I n  o u r  s t u d y ,  a m o n g  6 4  p a t i e n t s  i d e n t i f i e d  w i t h  A F ,
40.9% (n = 32) were discharged on oral anticoagulants,
selected according to the neurological and dependency
scales and excluding other contraindications, as current
evidence-based guidelines suggest [27], [28]. Through-
out-the follow-up of these patients (7-45 months), OAT
was shown as an efficient and safe treatment in these
selected patients, despite being a very old population (80-
89 years-old). With respect to haemorrhage risk, systemic
h a e m o r r h a g e s  w e r e  f o u n d  i n  o n l y  f o u r  c a s e s ,  w i t h o u t
modifying the M-Rankin scale, and they corresponded to
overtreated patients, as the INR reflected (mean 5.95).
We did not find any intracranial haemorrhage. Although
atrial fibrillation was present as a risk factor in more than
a half of cardioembolic strokes, only a quarter of these
patients were previously an adequate anticoagulant pro-
phylaxis.
In summary, we would like to remark the importance of
cardioembolic etiology in strokes of patients over 80
years, which contrasts with the scarcity in the appropriate
use of OAT as prophylaxis. According to our results,
stroke recurrence in patients on oral anticoagulation is
mainly ischemic, and haemorrhagic complications that
derive from oral anticoagulation would be related to
overdosing. Having into account that the population is
too small and the follow-up relatively short, this paper
suggests that OAT might be safe in cardioembolism pro-
phylaxis independently of age and may be effective if we
compare with natural history of not anticoagulated
patients [13], [14], [16], [20].
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